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Abstract
Protein classification typically uses structural, sequence, or functional similarity. Here we 
introduce an orthogonal method that organizes proteins by ligand similarity, focusing here on the 
class A G protein-coupled receptor (GPCR) protein family. Comparing a ligand-based dendogram 
to a sequence-based one, we sought examples of GPCRs that were distantly linked by sequence 
but neighbors by ligand similarity. Experimental testing of compounds predicted to link three of 
these new pairs confirmed the predicted association, with potencies ranging from the low-
nanomolar to low-micromolar. We then identified hundreds of non-GPCRs closely related to 
GPCRs by ligand similarity, including the CXCR2 chemokine receptor to Casein kinase I, the 
cannabinoid receptors to epoxide hydrolase 2, and the α2 adrenergic receptor to phospholipase D. 
These, too, were confirmed experimentally. Ligand similarities among these targets may reflect a 
chemical integration in the time domain of molecular signaling.
Introduction
Since the molecular biology revolution, proteins have been related to each other 
bioinformatically by either sequence or structural similarities.1,2 When we seek to 
understand the ligand recognition of a protein or the specificity of a drug or a reagent, we 
typically consider those proteins that are related structurally, functionally3, or by sequence4. 
Correspondingly, methods and databases of protein families such as Pfam5 and TRIBE-
MCL6 rely on multiple sequence alignments and machine learning to classify protein 
families.
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Ligand recognition does not always respect such molecular biology metrics. For instance, 
acetylcholine and serotonin signal both through G protein-coupled receptors (GPCRs) and 
ion channels, which are unrelated by sequence or structure. Both ligands are also recognized 
by specific transporters, which are, in turn, are unrelated to GPCRs and ion channels. In 
addition, drugs like alosetron, which target the ionotropic serotonin receptors (HTR3), also 
modulate the metabotropic serotonin receptors (e.g. HTR2B, HTR4),7,8 while serotonergic 
GPCR-targeting drugs also modulate the serotonin transporter.9 Ligands that modulate bile 
acid nuclear hormone receptor (NR1H4) also modulate the G protein-coupled bile acid 
receptor (GPBAR1)10. Inhibitors of enzymes, from reverse transcriptases to kinases to 
proteases, can also modulate GPCRs and nuclear hormone receptors.9,11–13
We thus wondered how a quantitative ligand-based organization of pharmacological targets 
might differ from the more familiar sequence- and structure-based approaches. It is easy, 
after all, to build a “just-so” story with a few selected cases, such as acetylcholine and 
serotonin, but to understand whether a ligand-based relationship among targets will 
substantially differ from a sequence-based one, the two schemes must be compared globally 
and quantitatively. Since sequence and structure comparisons are restricted to targets within 
a single, evolutionarily related target family, we will focus our attention on class A 
(rhodopsin-like) GPCRs. These targets are recommended by their abundance--about 700 
genes in the human genome14— and the substantial number that have annotated ligands.
Here we ask the following questions: how different is a sequence-based organization of the 
class A GPCRs from one based on ligand similarity? Do the differences explain non-obvious 
aspects of target pharmacology and drug discovery? Can we use the ligand-based 
organization prospectively, to predict and test new associations among previously unrelated 
targets? Whereas we and others15–17 have used ligand-based metrics to predict the activities 
of individual drugs against off-targets, this is, to our knowledge, the first effort to compare 
pharmacological relationships across an entire family of targets. The associations that 
emerge are startling: some GPCRs that are distant by sequence identity become neighbors 
by ligand similarity, while others that are neighbors by sequence are pushed far apart by the 
dissimilarity of their ligand sets. The ligand-based target similarities also suggest new 
associations among receptors that are, for the first time, predicted and demonstrated to share 
ligands. Because these associations are based on ligand similarities, they may be expanded 
to explore the polypharmacology between GPCRs and non-GPCRs, which are wholly 
unrelated by sequence and structure. An emergent property of these associations is that they 
recapitulate the activities of the cognate primary messengers, which also cross major target 
boundaries. This may reflect relationships in the time domain of molecular signaling, where 
ligand chemistry, not receptor sequence, is conserved.
Results
There were 146 class A GPCRs with at least six ligands in the ChEMBL database, which 
annotates ligands to targets based on literature reports.18 On average each GPCR had 608 
ligands, with a median of 380. Whereas this list captures a minority of the roughly 700 class 
A GPCR members14, all of the major sub-families are included, such as the biogenic amine 
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receptors, the peptide-receptors, the lipid-activated GPCRs, and receptors responding to 
protein ligands.
These GPCRs were organized by sequence and by ligand similarity. To focus on the part of 
the sequence most implicated in ligand binding, we only used those residues previously 
mapped to one of 43 orthosteric sites.19 Sequence distances between any pair of targets was 
measured using the Unweighted Pair Group Method with Arithmetic Mean (UPGMA) 
algorithm,20 and rendered using FigTree (http://tree.bio.ed.ac.uk/software/figtree/) (Fig. 1a); 
notwithstanding the focus on sequence identity in the binding site, the relationships that 
emerge resemble those based on dendograms using full receptor sequence identity (e.g., 
http://gpcr.scripps.edu/).
To associate receptors by ligand similarity, ligands were represented by topological 
fingerprints, which are bit strings that reflect the presence or absence of chemotypes and 
their chemical environment in the ligand. The similarity of these fingerprints was compared 
for all pairs of molecules in each ligand-set for each pair of receptors, and the overall 
similarity of these sets was compared to an expected random similarity using machinery 
drawn from the sequence algorithm Basic Local Alignment Search Tool (BLAST). 
Similarly, an expectation value (E-value) can be calculated, using the Similarity Ensemble 
Approach (Methods).11,21 Ligand-based dendrograms, too, were calculated using FigTree, 
with the distance between pairs of GPCRs quantified by the cosine angle of their SEA E-
values (Fig 1b).
In the sequence-based dendrogram, the relationships among the GPCRs are as expected. The 
biogenic amine receptors, including the adrenergic, dopaminergic and serotonergic GPCRs 
largely cluster together, as do peptidic receptors such as the chemokines and melanocortins, 
as do the lipid responding GPCRs. At a finer resolution, some peculiar divergences and 
associations begin to appear. For instance, the cysteinyl leukotriene and leukotriene B4 
receptors are separated from not only the other lipid-recognizing GPCRs, but also from each 
other, even though they are a part of the same 5-lipoxygenase pathway involved in airway 
inflammation.
Compared to the sequence-based organization, the ligand-based dendrogram seems 
victimized by almost grotesque rearrangements. The muscarinic receptors shift away from 
the other biogenic amine GPCRs and toward the chemokine receptors, with which they 
share very little orthosteric site sequence identity (9–21% identity across all subtypes). 
Equally perplexing, the β-adrenergic receptors separate from the α-adrenergic receptors and 
indeed other biogenic amine GPCRs, moving closer to the cannabinoid lipid receptors and 
melatonin receptors. Other rearrangements, though covering just as much distance, seem 
easier to reconcile with the biology they control. Thus, the cysteinyl leukotriene and 
leukotriene B4 receptors move much closer to each other than they were by sequence, and 
now cluster with other lipid GPCRs, consistent with their roles in the same leukotriene 
inflammatory pathway.
Though these rearrangements seem superficially perplexing, their basis may be grasped by 
comparing the ligands that bind to these targets. Many GPCRs that are dissimilar by 
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orthosteric site sequence bind similar ligands, to the point where exactly the same ligands 
are sometimes shared between them (Supplementary Table 1). For example, the opioid and 
somatostatin receptors shift closer to the biogenic amine receptors. Despite their sequence 
differences, these peptidic receptors often bind aminergic molecules. The SSTR5 
somatostatin 5 receptor and the HRH1 histamine H1 receptor, for instance, share only 33% 
sequence identity in their binding sites, even though their ligand sets resemble one another 
(E-value of 9.9 × 10−8; Supplementary Table 1). Indeed, the two receptors are modulated by 
several identical ligands22 (Supplementary Table 1).
Conversely, some receptors, like the muscarinic, the β-adrenergic, and the chemokine 
families, separate from apparently cognate GPCRs. Based on ligand similarity, the 
muscarinic receptors move closer to peptidic GPCRs, such as neuropeptide Y and 
chemokine receptors, and to lipid GPCRs, like sphingosine phosphate and prostaglandin 
receptors, and away from the biogenic amine receptors. Thus, whereas the CHRM1 
muscarinic acetylcholine receptor M1 and the MCHR1 Melanin-containing hormone 
receptor 1 share only 26% sequence identity in the binding site, their SEA E-value is 
8.3×10−7 and they share several sub-micromolar ligands23 (Supplementary Table 1). 
Meanwhile the muscarinics share few ligands, and little ligand-set similarity, with most 
bioaminergic receptors. The separation of the β- and α-adrenergics is explained by the 
divergence of their ligand sets. The two classes of receptors share adrenaline and 
noradrenaline as primary messengers, and have sequence identities ranging from 49% to 
63%, but once past the small catecholamines their ligands diverge: the β adrenergic ligands 
largely resemble isoproterenol, while the α adrenergic antagonists vary widely, often 
characterized by larger compounds with disparate scaffolds. Meanwhile, the chemokine 
receptors, which form an essentially contiguous family by sequence, are split into two 
groups by ligand similarity. One group, characterized by CXCR4, CCR1, CCR2, and CCR5, 
move closer to the biogenic amine receptors, while CCR3, CCR8 and CXCR3 move closer 
to the muscarinics and the neuropeptide Y receptors. For instance, though CCR5 and the 
CHRM2 muscarinic acetylcholine receptor M2 share only 16% sequence identity in the 
binding site, they share over 30 antagonists in several different ligand series (Supplementary 
Table 1).
Emboldened by these observations, we asked if the new associations predict crosstalk 
between targets not formerly known to share ligands. Many of the new neighbors in the 
ligand-based dendrogram share not even a single ligand, neither in ChEMBL nor in the 
literature, but nevertheless are highly related by the SEA E-values of their ligand lists. One 
such was the link between the OPRK κ opioid receptor and the HTR2B 5-HT2B serotonin 
receptor ligands, which resemble each other with a SEA E-value of 9.9 × 10−8 though their 
sites share only 28% sequence identity. A SEA-screen of the ZINC database24 suggested 
that compound 1 was similar to both the OPRK and HTR2B ligands. Upon in vitro testing, 
compound 1 had a Ki of 0.9 μM to HTR2B and 1.0 μM to OPRK (Fig. 2, Table 1). We note 
that after these experiments were concluded, another series of compounds were found by 
some of us, in an unrelated project, that also inhibited both targets. The chemical series that 
did so is unrelated to that described here25.
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If there have been many previous examples of ligand crosstalk between peptide and 
bioamine GPCRs, there are many fewer between peptide- and lipid-recognizing GPCRs. We 
were therefore interested to observe an association between the NPY5R neuropeptide Y 
receptor 5 and CNR2 cannabinoid receptor 2. Whereas their binding sites share only 7% 
identity, they had a SEA E-value of 1.1 × 10−9. A particular CNR2 agonist, compound 2, 
resembled NPY5R ligands and was commercially available (Table 1). Compound 2 was 
found bind to NPY5R with an IC50 of 190 nM (Ki = 8.5 nM), similar to its CNR2 potency 
(EC50 = 140 nM)26. NPY5R was also linked to the MTNR1B Melatonin receptor 1B, in yet 
another GPCR sub-clade, with a SEA E-value of 5.3 × 10−13. Here too, we found a 
particular MTNR1B agonist (EC50 = 14 μM), compound 3, that we measured to antagonize 
NPY5R with a Ki of 1.9 μM.
We next asked how many of the GPCRs were strongly related by ligand similarity to a 
sequence-unrelated target. Interrogating all of the ChEMBL ligand sets, there were 485 non-
GPCRs that resembled at least one GPCR in our dendrogram with an E-value of 1 × 10−10 
or better (lower). Similarity values ranged from this level, for the ligand sets of the EDG7 
lysophosphatidic acid GPCR and the enzyme Arachidonate 12-lipoxygenase (LOX12), to 3 
× 10−314 for the ligand sets of the NTSR1 neurotensin 1 GPCR and Sortilin (SORT). These 
non-GPCR targets covered most protein families including ion channels, enzymes, kinases, 
and glycoproteins. Indeed, there were so many non-GPCR to GPCR links that clarity only 
allowed us to show up to two for any given GPCR (Fig. 3).
Here again, many highly-related pairs shared no single ligand between them, and for a few 
we predicted and tested ligands that would bind to both targets. We started with CXCR2 and 
casein kinase 1 (KC1G1), linked by a SEA E-value of 1.3 × 10−15, and identified an 
inhibitor of the kinase that resembled the CXCR2 ligands. Compound 4 was tested and 
found to be an agonist for CXCR2 with an EC50 of 254 nM (Table 2, Fig. 4). More 
ambitiously, we searched for a compound that can inhibit a GPCR and an enzyme in the 
same pathway. One such link was between the α2 adrenergic receptors and their 
downstream phospholipase D1 and D2 (PLD1 and PLD2) enzymes27. Compound 5, a 
known phospholipase inhibitor, was tested against three α2 adrenergic receptor subtypes and 
had a Kd of 556 nM to the α2c sub-type (Table 2, Fig. 4).
Finally, we sought targets implicated not only in the same pathway, but also in a similar 
clinical indication. Among these were the cannabinoid receptors and the enzyme epoxide 
hydralase 2 (HYES), whose ligand sets have an E-value of 1.3 × 10−18. Intriguingly, both 
proteins are cardioprotectant targets and both are in the endocannabinoid pathway (epoxide 
hydrolase 2 deactivate epoxidated endocanniboids).28 We identified compound 6, an HYES 
inhibitor, as a potential CNR2 cannabinoid receptor 2 ligand. On testing, compound 6 had Ki 
values of 3.6 and 2.3 μM against CNR1 and CNR2, respectively (Table 2, Fig. 4).
Discussion
Relationships among targets are typically visualized by sequence-based family trees, and it 
is common to infer from these trees both on- and off-target pharmacology29. A key 
observation from this study is that when GPCRs are compared by ligand similarity, the 
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arborization of the family tree changes dramatically. Targets that are neighbors by sequence 
are separated, while targets that are distant by sequence become neighbors. This is reflected 
in targets that unexpectedly respond to the same drugs and reagents, and can predict 
sequence-distant neighbors that will share ligands where none were previously known. The 
predicted and confirmed cross-activity of ligands against the κ opioid and serotonin 
receptors, the cannabinoid and neuropeptide Y receptors, and the neuropeptide Y and 
melatonin receptors, is doubly unexpected. These pairs of targets not only share little residue 
identity in their orthosteric sites, from 7% to 28%, but they cross target boundaries among 
the GPCRs: from peptide to biogenic amine, lipid to peptide, and peptide to neutral small 
molecule. More startling still is the observation that many non-GPCRs strongly resemble 
GPCRs by ligand similarity (Fig. 3, Table 2). Whereas some of this undoubtedly reflects the 
conservatism of medicinal chemistry, it is impossible to look at the penumbra of non-
GPCRs that are strongly associated with GPCRs (Fig. 3) without wondering whether a more 
basic principle might be at work.
As sequence similarities reflect the action of evolution on proteins, the ligand-based 
dendograms may reflect the chemical pressures against which the receptors have evolved. 
Many primary signaling molecules themselves target receptors unrelated by sequence or 
structure. For instance, serotonin modulates both the HTR3 receptor, an ion channel, and the 
HTR1-2,4-7receptors, which are GPCRs. Acetylcholine targets the nicotinic receptors (ion 
channels) and the muscarinic receptors (GPCRs). Glutamate and GABA similarly both 
signal ionotropically and metabatropically. Leukotriene B4 activates GPCRs and the nuclear 
hormone PPARs. Estrogen binds to not only its eponymous nuclear hormone receptor but 
also to GPR30 (Supplementary Table 2).30
The promiscuity of primary signaling molecules reflects two constraints in biological 
signaling. First, cells respond to signals in multiple time domains: the millisecond, the 
second to minute, and the hour-to-day. To achieve this temporal resolution, they will often 
use ion channels, GPCRs, and nuclear hormone receptors, respectively. Second, these 
responses are evoked by a small repertoire of chemical messengers; once the machinery to 
synthesize, degrade, and regulate molecules like serotonin, acetylcholine, and estrogen is 
created, it is costly to change and becomes fixed.31 On the other hand, it is relatively easy 
for evolution to repurpose an ion channel to recognize serotonin or acetylcholine, or a GPCR 
to recognize glutamate. Thus, the ability of receptors across major sequence and fold 
boundaries to recognize related ligands, which is captured in the ligand-based dendograms, 
may reflect a core chemo-evolutionary constraint in molecular signaling. If true, then probe 
and drug polypharmacology is neither epiphenomenal nor capricious, but reflects the 
evolution of signaling relationships in the time domain. Pragmatically, the associations 
among unrelated targets, revealed in the ligand-based dendograms, may suggest joint targets 
for a single molecule. Known examples are drugs that bind to both ionotropic and 
metabatropic serotonin receptors, like alosetron, or that bind to both muscarinic receptors 
and acetylcholinesterase, like flaxedil (Fig. 3). Meanwhile, the discovery that compound 6 
modulates both cannabinoid GPCRs and epoxide hydrolase 2 is consistent with a role for 
this enzyme in the degradation pathway of the endocannabinoids, potentially arresting their 
signaling.28
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Several weaknesses in this approach merit airing. Most prominently, a ligand-based view 
remains inference-based: targets for which no ligands are known are invisible to it, and even 
when ligands are known they can never be known perfectly, unlike the protein sequence. 
Mechanically, SEA remains imperfect, here, as previously,7,12,32 the method had a 50% 
false-positive rate, with six of twelve predictions falsified by experiment (Supplementary 
Table 3). Pharmacologically, finding a ligand to modulate a GPCR and an enzyme in vitro 
does not guarantee intracellular enzyme inhibition in vivo, though GPCR activity of an 
enzyme inhibitor may be more likely. Also, we do not currently distinguish among agonists 
and antagonists, nor even between allosteric and orthosteric ligands; the conflation of these 
for a single receptor weakens the signal on which SEA operates. Meanwhile, in some 
protein families, such as the kinases, ligand-based and sequence-based dendrograms may 
resemble each other more closely than do the GPCRs, since the binding site environments 
are more similar and the proteins bind a single or closely related native ligand.
These cautions should not obscure the central observation from this study: a systematic and 
comprehensive ligand-based receptor organization differs startlingly from the more familiar 
sequence-based view. If this approach is weakened by ligand-based inference, it is also true 
that at least one other chemoinformatic approach, using only partially overlapping ligands 
and GPCRs, results in a dendogram with receptor associations and disassociations that 
resemble those observed here29. Pragmatically, ligand-based organizations of receptors offer 
a guide to the off-targets of tool and therapeutic molecules that is orthogonal to, but 
sometimes as illuminating as, the sequence-based view. More broadly, the association of 
485 non-GPCRs with GPCRs by ligand similarity suggests a model for polypharmacology 
that reflects to the roles of primary messengers in cellular signaling. A virtue of this model is 
that it leads naturally to testable hypotheses, articulated through the very molecules that are 
the basis of the ligand-based organization. Some of these are suggested by the dendrograms 
investigated here (Fig. 3).
Online Methods
Sequences and structural alignment
The initial transmembrane sequence alignments were downloaded and filtered for human 
sequences only. The 43 binding site residues described by Gloriam DE et. al.19 were then 
extracted for all human sequences, maintaining the sequence alignments.
Annotated ligands
The ligands and affinity data were downloaded from ChEMBL (version 7) and filtered by 
their binding affinity values to create sets of ligands for targets if their IC50, Kd, Ki or EC50 
were 10μM or less. Ligands were also filtered by molecular weight (under 700), nitrogen 
count (fewer than eight) and oxygen count (fewer than eight) to remove large molecules and 
peptides. The ChEMBL database does not explicitly differentiate between agonists and 
antagonists for its ligands and here we combine both into the same ligand-set for each GPCR 
without differentiating their functional activity. 146 human GPCR sets and 2090 non-GPCR 
protein sets were assembled that each contained at least five annotated ligands and were 
used to compare using SEA.
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Binding site sequence alignments were used to calculate relative distances between all 146 
GPCRs that had ligand sets associated with them. The Unweighted Pair Group Method with 
Arithmetic Mean (UPGMA) algorithm was used in MEGA 3.133 to produce the pairwise 
distance matrix between all GPCRs. Similarities ranged from just 5% to 88% identity in the 
binding sites with an average of 23%.
The ligand sets were also used to calculate relative distances between all 146 GPCRs by 
using SEA11 to obtain E-values between each GPCR. Each ligand was broken down into 
molecular fingerprints; here Extended Connectivity Fingerprints (ECFPs) 34 were used. 
Briefly, ECFPs are circular topological fingerprints that represent molecular structures by 
small atom neighborhoods or substructures, along with their physical chemical properties. 
The similarity between any pair of bit strings (molecules) is quantified by the bits they share 
in common divided by the total number of bits, via the Tanimoto coefficient (Tc)35. The 
sum of all Tc values over a certain cutoff between all the molecules in the two target-ligand 
sets is then calculated and compared to what we would expect for two sets of ligands, of the 
same set size, randomly drawn from ChEMBL. The ratio of the observed sum of Tc values 
to that expected at random is divided by the standard deviation of the random similarity to 
give a Z-score; when plotted against an extreme value distribution, this gives an expectation 
value (E-value). The E-values were then logged and used to calculate the pairwise cosine 
angle. The cosine angle was used as the distance metric, since E-values are not necessarily 
completely correlative with similarity, rather we use them as more of a binary measure with 
E-values less (better) than 1×10−5 as significant and anything greater (worse) taken as 
insignificant. Therefore, using the cosine angle, the magnitude of the E-value is not over-
weighed such that E-values of 1×10−300 and 1×10−20 are treated about the same since they 
are both significant E-values. Similarity between GPCRs and non-GPCRs were calculated in 
the same way, using the annotated ligand sets as surrogates for the protein to calculate SEA 
E-values. The two lowest E-values between each GPCR and the non-GPCRs were retained.
Dendrograms
Using the similarity distance matrices of the binding site sequences and ligand sets, 
dendrograms were constructed using FigTree. The distance matrices were inputted in 
Newick format and a radial tree format was used for the layout. The spread was increased to 
better distinguish the proteins that are highly similar to each other. Nodes were further 
expanded out in Adobe Illustrator for legibility and color coded based on the chemistry of 
their endogenous ligands, e.g. peptide, bioamine, lipid, and so forth. The two non-GPCRs 
with the lowest E-value was drawn on using Adobe Illustrator and linked to their respective 
GPCRs. The non-GPCRs in bold and italicized represent those non-GPCRs that have a 
known shared ligand with the GPCR.
Radioligand competition binding assays
Standard techniques were used 36 at the NIMH Psychoactive Drug Screening Program.
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CXCR2 β-Arrestin Recruitment Tango Assay
Recruitment of β-arrestin to agonist-stimulated CXCR2 receptors was performed using a 
previously described “Tango”-type assay. 37 Briefly, HTLA cells stably expressing β-
arrestin-TEV protease and a tetracycline transactivator-driven luciferase were plated in 10-
cm dishes in DMEM containing 10% FBS and transientlytransfected (via calcium 
phosphate) with 10 μg of a CXCR2-V2-TCS-tTA construct. The next day, cells were plated 
in white, clear-bottom, 384-well plates (Greiner; 15,000 cells/well, 50 μL/well) in DMEM 
containing 1% dialyzed FBS and incubated overnight at 37°C. The following day, cells were 
challenged with 10 μL/well of reference agonist or CXCR2 test ligand (CXCL6 and 
CXCL8) at evenly distributed concentrations that ranged from 6 pM to 60 μM prepared in 
HBSS, 20 mM Hepes, pH 7.4, and 6% DMSO (final ligand concentrations are 1 pM to 10 
μM, final DMSO concentration is 1%). After 18 h, the medium was removed and replaced 
with 1× BriteGlo reagent (Promega), and luminescence per well was read using a TriLux 
plate reader (1 s/well). Data were normalized to vehicle (0%) and reference compound 
(100%) controls and regressed using the sigmoidal dose-response function built into 
GraphPad Prism 5.0.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Dendrograms of human GPCRs with annotated ligands from ChEMBL. Organization based 
on (a) sequence similarity in the binding site and (b) ligand set similarity based on SEA E-
values. Color coding is based on chemistry of their endogenous ligands (i.e. Bioamines 
(blue), melatonins (gold), lipids (green), peptides (black), purinergics (dark blue), 
adenosines (light blue), orphans (red).).
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Dose-response curves of new GPCR cross-activities. (a–e) Radioligand competition binding 
assay: compound 1 at HTR2B (a) and OPRK (b), compound 2 at NPY5R (c), compound 3 
at MTR1B (d) and NPY5R (e). Data represent mean values ± s.e.m, performed on triplicate 
experiments.
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Non-GPCRs (orange) highly-related to particular GPCRs by ligand similarity (color code is 
as in Figure 1). Bolded targets have known ligands that bind to both the GPCR and non-
GPCR target. Links that share known messengers are labeled in black in parenthesis.
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Dose-response curves of new GPCR cross-activities with non-GPCRs. Testing new GPCR 
cross-activities with non-GPCRs. β-Arrestin Recruitment Tango Assay: compound 4 at 
CXCR2 (a), competition binding assay: compound 5 at α2c Adrenergic receptor (b), 
compound 6 at CNR1 (c) and CNR2 (d). Data represent mean values ± s.e.m, performed on 
triplicate experiments.
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